In a small study at the Imperial College of London, 19 patients received a single dose of the psychedelic psilocybin. All had been diagnosed with, and were suffering from, depression that had been resistant to treatment. Twenty four hours after the ingestion of psilocybin, brain scans revealed that the amygdala, involved in how emotions such as fear and anxiety are perceived, was less active. The "default-mode network", a collaboration of different brain regions, had grown much calmer. Patients used such terms as "reset" to describe their subjective response to the novel therapy.
"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms," Nature, 1 June 2017
https://www.nature.com/articles/s41598-017-13282-7
"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms," Nature, 1 June 2017
https://www.nature.com/articles/s41598-017-13282-7
